Mobini N, Sarela A, Ahmed A R
Boston University School of Medicine, Department of Dermatology, Massachusetts.
Ann Allergy Asthma Immunol. 1995 Feb;74(2):119-28; quiz 128-33.
The focus of this review is to summarize the mechanism and the adverse side-effects of Intravenous Immunoglobulin (IVIg) therapy, and to highlight the current cumulative experience of its use in the treatment and management of autoimmune and systemic inflammatory diseases.
Detailed search of the literature was done. Studies involving only humans were considered for clinical evaluation. Animal studies were used only for understanding mechanisms of action. The NIH Consensus Conference of May 1990 and the Australian Society for Blood Transfusion of July 1993 were used for guidelines.
Material was taken only from peer reviewed journals.
It appears that IVIg may act by more than one mechanism of action. It is unclear whether the mechanism is different in different diseases and whether more than one mechanism may apply to any disease or clinical state. The incidence and gravity of serious side effects appears low. It is the mainstay of treatment of immune thrombocytopenia purpura and Kawasaki disease.
IVIg is a safe and effective therapeutic modality that can be added to the repertoire of various agents used to treat autoimmune and systemic inflammatory diseases. Long-term prospective studies are needed to define indications, dose-schedules, duration of therapy, and influence on the clinical courses of chronic diseases better.
本综述的重点是总结静脉注射免疫球蛋白（IVIg）治疗的机制和不良反应，并强调其在自身免疫性疾病和全身性炎症性疾病治疗与管理中的当前累积应用经验。
对文献进行了详细检索。仅纳入涉及人类的研究进行临床评估。动物研究仅用于理解作用机制。采用1990年5月的美国国立卫生研究院共识会议和1993年7月的澳大利亚输血协会的指南。
资料仅取自同行评审期刊。
IVIg似乎可能通过多种作用机制发挥作用。尚不清楚不同疾病中的机制是否不同，以及任何疾病或临床状态是否可能适用多种机制。严重副作用的发生率和严重程度似乎较低。它是免疫性血小板减少性紫癜和川崎病治疗的主要手段。
IVIg是一种安全有效的治疗方式，可添加到用于治疗自身免疫性疾病和全身性炎症性疾病的各种药物中。需要进行长期前瞻性研究，以更好地确定适应症、剂量方案、治疗持续时间以及对慢性病临床病程的影响。
